Cardiovascular Systems

Cardiovascular Systems Operating Expenses

Delisted

The Total Operating Expenses of Cardiovascular Systems (CSII) as of Nov 16, 2026 is 207.25 M USD. In the previous year, Total Operating Expenses was 208.56 M USD — a change of -0.63% (lower).

Operating Expenses

207.25 MUSD

YoY

-0.63%

Last updated:

Total Operating Expenses of Cardiovascular Systems is 2022 207.25 M USD. Total Operating Expenses of Cardiovascular Systems was 2021 208.56 M USD. It decreases by -0.63% lower compared to the previous year.

The Cardiovascular Systems Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2015
174.66 M USD
Jan 1, 2016
188.48 M USD
Jan 1, 2017
167.01 M USD
Jan 1, 2018
175.33 M USD
Jan 1, 2019
201.16 M USD
Jan 1, 2020
213.32 M USD
Jan 1, 2021
208.56 M USD
Jan 1, 2022
207.25 M USD
The Cardiovascular Systems Operating Expenses history
YEAROperating ExpensesYoY
207.25 MUSD-0.63%
208.56 MUSD-2.23%
213.32 MUSD+6.05%
201.16 MUSD+14.74%
175.33 MUSD+4.98%
167.01 MUSD-11.39%
188.48 MUSD+7.91%
174.66 MUSD+25.60%
139.06 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardiovascular Systems stock

Total Operating Expenses of Cardiovascular Systems is 207.25 M USD in 2022.

Total Operating Expenses of Cardiovascular Systems changed from 208.56 M USD to 207.25 M USD, representing a -0.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Cardiovascular Systems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems